Ground-breaking treatment offers new hope for patients with persecutory delusions
8 July 2021
- 70% of patients with severe mental health difficulties experience persecutory delusions
- Patients taking part in the trial had persecutory delusions despite treatment with antipsychotic medication
- 50% of the patients achieved recovery from their persecutory delusions using the new psychological treatment
A new treatment programme for persecutory delusions promises a step change in the treatment of severe mental health problems. The clinical trial results show that the new Feeling Safe programme is the most effective psychological treatment for persecutory delusions.
Persecutory delusions – unfounded, strongly held beliefs that other people intend to harm us – have traditionally been regarded as a key symptom of psychiatric diagnoses such as schizophrenia. Fearing harm from those around them, patients often withdraw from ordinary life. The negative consequences of this withdrawal, for patients and family alike, can be profound.
The Feeling Safe programme was developed by researchers from the University of Oxford, who tested the treatment in a randomised controlled trial with 130 patients with persecutory delusions. The delusions had persisted despite use of standard treatments. The results are published today in the Lancet Psychiatry. Half of patients were found to achieve large benefits from the Feeling Safe programme, with a further quarter making moderate gains. The trial was funded by the National Institute for Health Research (NIHR) and the NIHR Research Professorships. It was also supported by the NIHR Oxford Health Biomedical Research Centre.
NIHR Research Professor Daniel Freeman, the developer of the Feeling Safe programme, Department of Psychiatry, University of Oxford, said: ‘Feeling Safe is the result of more than ten years of research and clinical practice. Its success has been built on listening carefully to patients, to really understand the causes of the problems they are facing. The trial results give us great cause for optimism in the treatment of a problem that is very common in people with psychosis, immensely distressing for patients and families, and yet often does not improve sufficiently with current treatments.
‘Over twenty sessions, the programme helps people to develop new memories of safety and addresses the factors that often maintain persecutory thoughts, such as worry, poor sleep, and low self-confidence. Feeling Safe is personalised and modular. Patients choose their preferred treatment elements and the order in which they undertake them. It’s an active therapy, based on the belief that people make gains by trying out things in everyday life. The results of the trial have been extremely pleasing. The challenge now is to reach the many thousands of people whose lives have been disrupted by severe paranoia.’
Persecutory delusions are typically treated with anti-psychotic drugs, but too many patients do not respond and side effects can be unpleasant. Four out of five patients with persecutory delusions are unemployed and spend less time in social and leisure activities and more time resting and ‘doing nothing’ compared with the general population. Life expectancy is on average 14.5 years shorter, due to largely preventable conditions such as high blood pressure, diabetes and heart disease -- illness to which inactivity is likely a major contributory factor.
Dr Felicity Waite, clinical psychologist in the Department of Psychiatry, University of Oxford, said: ‘So many of the patients we visited were spending virtually all their time at home. They were acutely aware of all that they were missing out on. Our aim was to bring them back into everyday life, to help them get back to the things they like doing. The enthusiasm with which people have participated in the Feeling Safe programme, and the positive change it has brought about, has been wonderful to see.’
A participant in the Feeling Safe trial said: ‘I was housebound. I missed out on so many things in life. I missed out on meeting my friends, family events, meals, training, sports, I was just in a very paranoid state. After a life-changing study – for me – I feel very, very safe. It worked. It really did. It helped massively.
You get better sleep, feel more confident, be more active in the day. Genuinely, inside I feel very happy. It’s profoundly changed my life. I don’t have to worry any more about people potentially attacking me or thinking sometimes there’s a weapon in their pocket. That’s all floated away.’
Notes to editor:
For interview requests and a pre-embargo copy of the paper, contact Gen Juillet, Media Relations Manager, email@example.com
This new paper, ‘Comparison of a theoretically driven cognitive therapy (the Feeling Safe Programme) with befriending for the treatment of persistent persecutory delusions: a parallel, single-blind, randomised controlled trial’, is published in the Lancet Psychiatry at: https://doi.org/10.1016/S2215-0366(21)00158-9
Post embargo link: http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00158-9/fulltext
A downloadable video explainer about the trial is available: https://www.youtube.com/watch?v=vUUxrts25XU
Professor Daniel Freeman is a consultant clinical psychologist in Oxford Health NHS Foundation Trust
The three NHS Trusts involved in the research are Oxford Health NHS Foundation Trust, Northamptonshire Healthcare NHS Foundation Trust and Berkshire Healthcare NHS Foundation Trust.
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions. · The NIHR Oxford Health Biomedical Research Centre is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford.
The University Department of Psychiatry’s mission is to conduct world-class research, teach psychiatry to medical students, develop future researchers in a graduate programme, teach doctors in training, promote excellence in clinical practice, and develop and provide innovative clinical services. It supports research in four key areas: neurobiology, psychological treatments, developmental psychiatry and social psychiatry. The Department is committed to the translation of scientific discovery into benefits for patients. www.psych.ox.ac.uk
About the NIHR
The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
- Funding high quality, timely research that benefits the NHS, public health and social care;
- Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
- Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
- Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
- Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
- Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.
NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.